PET molecular imaging for pathophysiological visualization in Alzheimer's disease

Area of Science:

• Neuroscience
• Medical Imaging
• Biomarkers

Background:

• Alzheimer's disease (AD) is the leading cause of dementia globally, posing a significant societal burden due to unclear etiology and lack of effective treatments.
• AD is a complex, heterogeneous condition where dynamic biomarkers are crucial for assessing severity and prognosis.
• Current diagnostic and prognostic tools for AD are limited, necessitating advanced imaging techniques.

Purpose of the Study:

• To review the application of Positron Emission Tomography (PET) in understanding Alzheimer's disease.
• To summarize radiolabeled compounds used in PET imaging for AD.
• To highlight PET's role in comprehensive pathomechanism exploration and biomarker identification across AD phases.

Main Methods:

• Literature review focusing on PET imaging in Alzheimer's disease.
• Analysis of various radiolabeled agents and their application in PET scans.
• Discussion of PET's utility in visualizing pathophysiological processes in AD.

Main Results:

• PET imaging provides diverse perspectives for visualizing Alzheimer's disease.
• Radiolabeled compounds enable the exploration of various pathophysiological processes in AD.
• PET facilitates the identification of appropriate biomarkers for different stages of AD.

Conclusions:

• PET imaging is a valuable tool for comprehensively exploring Alzheimer's disease pathomechanisms.
• A range of biomarkers visualized through PET is essential for evaluating AD severity and prognosis.
• PET offers a promising avenue for improved AD evaluation and management through advanced imaging.